Body and co-workers (Body et al., 2003) stated that OPG was accepted as a treatment for patients with bone disease related to breast carcinoma or multiple myeloma and is thus effective in reducing levels of bone resorption markers. Here, TNFRSF11B is linked to plasma cell myeloma.